GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Total Long-Term Liabilities

Mabion (WAR:MAB) Total Long-Term Liabilities : zł8.94 Mil (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Mabion Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Mabion's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was zł8.94 Mil.


Mabion Total Long-Term Liabilities Historical Data

The historical data trend for Mabion's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Total Long-Term Liabilities Chart

Mabion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.74 51.14 34.79 35.37 35.16

Mabion Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.16 34.99 9.55 9.15 8.94

Mabion Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Mabion Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Mabion's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabion Business Description

Industry
Traded in Other Exchanges
N/A
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion Headlines